Jefferies Cuts Price Target on Immune Design (IMDZ) Following 4Q

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. ANT
3. SPY
4. FFAI
5. FFR
6. CART
7. LLY
8. TSLA
9. META
10. FICO

Go back to Jefferies Cuts Price Target on Immune Design (IMDZ) Following 4Q

Immune Design Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update

March 10, 2016 4:01 PM EST

SEATTLE and SOUTH SAN FRANCISCO, Calif., March 10, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), a clinical-stage immunotherapy company focused on oncology, today reported financial results and a corporate update for the fourth quarter and full year ended December 31, 2015.

Corporate Update and Recent Highlights

New positive data support continued development of Immune Designs wholly-owned immuno-oncology product candidates.

LV305, the novel vector component of CMB305 that delivers NY-ESO-1 RNA specifically to dendritic cells in vivo, has achieved full patient enrollment in the Phase 1... More